Ridolfi, Ruggero <br/><br/>
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Mar 2002 
 - 1600-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2002.20.6.1600  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carmustine--administration & dosage<br/>Cisplatin--administration & dosage<br/>Dacarbazine--administration & dosage<br/>Female<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Interleukin-2--administration & dosage<br/>Italy<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Outpatients<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Quality of Life<br/>Recombinant Proteins<br/>Skin Neoplasms--drug therapy<br/>Surveys and Questionnaires<br/>Treatment Outcome